The global GLP-1 market, valued at USD 47.74 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 10.9% from 2025 to 2034, driven by the rising prevalence of type 2 diabetes, obesity, and metabolic syndrome, coupled with the expanding therapeutic applications of glucagon-like peptide-1 (GLP-1) receptor agonists. These injectable biologics—originally developed...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek